Quarterly Holdings Report
for
Fidelity® MSCI Health Care Index ETF
April 30, 2024
T05-NPRT3-0624
1.9584810.110
Schedule of Investments April 30, 2024 (Unaudited)
Showing Percentage of Net Assets
Common Stocks – 99.8% | |||
Shares | Value | ||
BIOTECHNOLOGY – 18.0% | |||
Biotechnology – 18.0% | |||
4D Molecular Therapeutics, Inc. (a) | 13,435 | $ 321,500 | |
89bio, Inc. (a) | 38,745 | 329,720 | |
AbbVie, Inc. | 889,663 | 144,694,790 | |
ACADIA Pharmaceuticals, Inc. (a) | 53,575 | 895,238 | |
ADMA Biologics, Inc. (a) | 109,562 | 714,344 | |
Agios Pharmaceuticals, Inc. (a) | 28,348 | 921,310 | |
Akero Therapeutics, Inc. (a) | 26,716 | 531,381 | |
Akouos, Inc. (a)(b) | 11,863 | 9,846 | |
Alector, Inc. (a) | 35,588 | 180,787 | |
Alkermes PLC (a) | 79,272 | 1,945,335 | |
Allogene Therapeutics, Inc. (a) | 54,542 | 150,536 | |
Alnylam Pharmaceuticals, Inc. (a) | 63,304 | 9,112,611 | |
Alpine Immune Sciences, Inc. (a) | 16,241 | 1,049,006 | |
Altimmune, Inc. (a) | 27,103 | 177,525 | |
ALX Oncology Holdings, Inc. (a) | 11,292 | 192,190 | |
Amgen, Inc. | 269,685 | 73,877,509 | |
Amicus Therapeutics, Inc. (a) | 111,275 | 1,111,637 | |
AnaptysBio, Inc. (a) | 5,367 | 130,633 | |
Anavex Life Sciences Corp. (a) | 41,670 | 152,096 | |
Apellis Pharmaceuticals, Inc. (a) | 35,855 | 1,584,432 | |
Apogee Therapeutics, Inc. (a) | 10,532 | 529,760 | |
Arcellx, Inc. (a) | 14,361 | 718,337 | |
Arcturus Therapeutics Holdings, Inc. (a) | 12,005 | 306,968 | |
Arcus Biosciences, Inc. (a) | 23,940 | 364,606 | |
Ardelyx, Inc. (a) | 117,085 | 749,344 | |
Arrowhead Pharmaceuticals, Inc. (a) | 61,761 | 1,397,034 | |
ARS Pharmaceuticals, Inc. (a) | 18,537 | 161,272 | |
Aurinia Pharmaceuticals, Inc. (a) | 67,248 | 342,292 | |
Avid Bioservices, Inc. (a) | 30,945 | 236,110 | |
Avidity Biosciences, Inc. (a) | 35,958 | 867,667 | |
Beam Therapeutics, Inc. (a) | 34,935 | 741,321 | |
BioCryst Pharmaceuticals, Inc. (a) | 93,730 | 387,105 | |
Biogen, Inc. (a) | 73,015 | 15,685,082 | |
Biohaven Ltd. (a) | 36,436 | 1,413,717 | |
BioMarin Pharmaceutical, Inc. (a) | 94,901 | 7,664,205 | |
Biomea Fusion, Inc. (a) | 11,268 | 121,018 | |
Blueprint Medicines Corp. (a) | 28,937 | 2,643,106 | |
Bridgebio Pharma, Inc. (a) | 52,662 | 1,349,200 | |
Cabaletta Bio, Inc. (a) | 15,122 | 160,974 | |
Cargo Therapeutics, Inc. (a) | 7,277 | 138,991 | |
Catalyst Pharmaceuticals, Inc. (a) | 53,376 | 803,309 | |
Celldex Therapeutics, Inc. (a) | 29,257 | 1,094,797 | |
Cerevel Therapeutics Holdings, Inc. (a) | 36,577 | 1,562,204 | |
Chinook Therapeutics, Inc. (a) | 24,218 | 0 | |
Cogent Biosciences, Inc. (a) | 31,403 | 204,120 | |
Crinetics Pharmaceuticals, Inc. (a) | 32,209 | 1,411,398 | |
CRISPR Therapeutics AG (a) | 38,087 | 2,018,230 |
| |||
Shares | Value | ||
Cullinan Therapeutics, Inc. (a) | 17,915 | $ 483,884 | |
Cytokinetics, Inc. (a) | 44,525 | 2,730,273 | |
Day One Biopharmaceuticals, Inc. (a) | 23,937 | 409,323 | |
Deciphera Pharmaceuticals, Inc. (a) | 17,635 | 445,636 | |
Denali Therapeutics, Inc. (a) | 55,079 | 850,420 | |
Disc Medicine, Inc. (a) | 6,080 | 169,267 | |
Dynavax Technologies Corp. (a) | 61,963 | 704,519 | |
Dyne Therapeutics, Inc. (a) | 21,792 | 551,556 | |
Editas Medicine, Inc. (a) | 36,783 | 191,639 | |
Entrada Therapeutics, Inc. (a) | 5,386 | 63,824 | |
Exact Sciences Corp. (a) | 91,301 | 5,418,714 | |
Exelixis, Inc. (a) | 141,154 | 3,311,473 | |
Fusion Pharmaceuticals, Inc. (a) | 21,923 | 469,810 | |
Geron Corp. (a) | 211,680 | 831,902 | |
Gilead Sciences, Inc. | 627,873 | 40,937,320 | |
Halozyme Therapeutics, Inc. (a) | 66,821 | 2,545,880 | |
HilleVax, Inc. (a) | 9,688 | 127,882 | |
Ideaya Biosciences, Inc. (a) | 28,464 | 1,157,062 | |
ImmunityBio, Inc. (a) | 68,632 | 548,370 | |
Immunome, Inc. (a) | 18,259 | 256,722 | |
Immunovant, Inc. (a) | 25,310 | 694,506 | |
Incyte Corp. (a) | 95,851 | 4,989,045 | |
Inhibrx, Inc. (a) | 10,731 | 365,283 | |
Insmed, Inc. (a) | 68,963 | 1,704,765 | |
Intellia Therapeutics, Inc. (a) | 43,096 | 922,254 | |
Ionis Pharmaceuticals, Inc. (a) | 65,252 | 2,692,298 | |
Iovance Biotherapeutics, Inc. (a) | 96,826 | 1,140,610 | |
Ironwood Pharmaceuticals, Inc. (a) | 71,660 | 555,365 | |
iTeos Therapeutics, Inc. (a) | 11,392 | 122,350 | |
Janux Therapeutics, Inc. (a) | 8,152 | 464,664 | |
Keros Therapeutics, Inc. (a) | 12,996 | 732,844 | |
Kiniksa Pharmaceuticals Ltd. Class A (a) | 14,863 | 278,235 | |
Krystal Biotech, Inc. (a) | 9,333 | 1,429,069 | |
Kura Oncology, Inc. (a) | 25,616 | 502,586 | |
Kymera Therapeutics, Inc. (a) | 20,359 | 684,470 | |
Lyell Immunopharma, Inc. (a) | 61,358 | 133,147 | |
MacroGenics, Inc. (a) | 23,466 | 346,827 | |
Madrigal Pharmaceuticals, Inc. (a) | 5,962 | 1,216,367 | |
MannKind Corp. (a) | 137,124 | 563,580 | |
Merus NV (a) | 19,153 | 860,161 | |
MiMedx Group, Inc. (a) | 57,201 | 352,358 | |
Mirum Pharmaceuticals, Inc. (a) | 15,058 | 378,106 | |
Moderna, Inc. (a) | 163,317 | 18,015,498 | |
MoonLake Immunotherapeutics (a) | 8,946 | 365,981 | |
Morphic Holding, Inc. (a) | 15,268 | 416,358 | |
Myriad Genetics, Inc. (a) | 44,641 | 873,624 | |
Natera, Inc. (a) | 57,569 | 5,347,009 | |
Neurocrine Biosciences, Inc. (a) | 49,558 | 6,816,207 | |
Novavax, Inc. (a) | 53,919 | 233,469 | |
Nuvalent, Inc. Class A (a) | 13,106 | 902,741 |
2 | Quarterly Report |
Schedule of Investments (Unaudited)–continued
Common Stocks – continued | |||
Shares | Value | ||
BIOTECHNOLOGY – continued | |||
Biotechnology – continued | |||
Olema Pharmaceuticals, Inc. (a) | 18,662 | $ 189,793 | |
Protagonist Therapeutics, Inc. (a) | 23,665 | 594,228 | |
Prothena Corp. PLC (a) | 19,894 | 404,644 | |
PTC Therapeutics, Inc. (a) | 33,947 | 1,091,396 | |
Radius Health, Inc. (a)(b) | 20,244 | 0 | |
Rapt Therapeutics, Inc. (a) | 11,615 | 89,436 | |
Recursion Pharmaceuticals, Inc. Class A (a) | 78,806 | 616,263 | |
Regeneron Pharmaceuticals, Inc. (a) | 53,979 | 48,076,936 | |
REGENXBIO, Inc. (a) | 20,821 | 319,602 | |
Relay Therapeutics, Inc. (a) | 40,784 | 265,912 | |
Replimune Group, Inc. (a) | 17,164 | 108,991 | |
REVOLUTION Medicines, Inc. (a) | 50,912 | 1,897,999 | |
Rhythm Pharmaceuticals, Inc. (a) | 23,925 | 951,258 | |
Rocket Pharmaceuticals, Inc. (a) | 31,843 | 685,261 | |
Roivant Sciences Ltd. (a) | 141,904 | 1,546,754 | |
Sage Therapeutics, Inc. (a) | 27,543 | 383,949 | |
Sana Biotechnology, Inc. (a) | 49,298 | 443,682 | |
Sarepta Therapeutics, Inc. (a) | 42,469 | 5,379,124 | |
Savara, Inc. (a) | 37,556 | 172,006 | |
Scholar Rock Holding Corp. (a) | 20,021 | 293,708 | |
Soleno Therapeutics, Inc. (a) | 7,676 | 342,810 | |
SpringWorks Therapeutics, Inc. (a) | 23,452 | 1,094,974 | |
Spyre Therapeutics, Inc. (a) | 9,996 | 330,168 | |
Summit Therapeutics, Inc. (a) | 68,603 | 269,610 | |
Syndax Pharmaceuticals, Inc. (a) | 38,490 | 813,294 | |
Tango Therapeutics, Inc. (a) | 19,786 | 152,352 | |
TG Therapeutics, Inc. (a) | 72,599 | 991,702 | |
Tourmaline Bio, Inc. | 8,184 | 129,553 | |
Travere Therapeutics, Inc. (a) | 37,549 | 207,646 | |
Twist Bioscience Corp. (a) | 29,217 | 912,447 | |
Ultragenyx Pharmaceutical, Inc. (a) | 37,288 | 1,586,232 | |
United Therapeutics Corp. (a) | 23,601 | 5,530,422 | |
Vaxcyte, Inc. (a) | 45,370 | 2,747,154 | |
Vera Therapeutics, Inc. (a) | 15,609 | 616,712 | |
Veracyte, Inc. (a) | 36,822 | 720,607 | |
Vericel Corp. (a) | 22,961 | 1,053,221 | |
Vertex Pharmaceuticals, Inc. (a) | 129,850 | 51,006,378 | |
Verve Therapeutics, Inc. (a) | 25,363 | 152,432 | |
Viking Therapeutics, Inc. (a) | 42,871 | 3,411,674 | |
Vir Biotechnology, Inc. (a) | 47,068 | 398,195 | |
Viridian Therapeutics, Inc. (a) | 20,959 | 277,916 | |
Xencor, Inc. (a) | 27,928 | 584,812 | |
Xenon Pharmaceuticals, Inc. (a) | 31,444 | 1,278,199 | |
Zentalis Pharmaceuticals, Inc. (a) | 24,428 | 270,174 | |
Zymeworks, Inc. (a) | 21,801 | 187,053 | |
TOTAL BIOTECHNOLOGY | 536,036,525 | ||
HEALTH CARE EQUIPMENT & SUPPLIES – 20.1% | |||
Health Care Equipment – 18.8% | |||
Abbott Laboratories | 874,793 | 92,701,814 |
| |||
Shares | Value | ||
Alphatec Holdings, Inc. (a) | 47,129 | $ 594,768 | |
Artivion, Inc. (a) | 19,115 | 375,036 | |
AtriCure, Inc. (a) | 23,928 | 577,143 | |
Axonics, Inc. (a) | 25,543 | 1,700,398 | |
Baxter International, Inc. | 255,133 | 10,299,719 | |
Becton Dickinson & Co. | 145,897 | 34,227,436 | |
Boston Scientific Corp. (a) | 738,211 | 53,055,225 | |
CONMED Corp. | 15,424 | 1,048,524 | |
DexCom, Inc. (a) | 194,696 | 24,802,323 | |
Edwards Lifesciences Corp. (a) | 305,620 | 25,876,845 | |
Enovis Corp. (a) | 24,559 | 1,356,394 | |
Envista Holdings Corp. (a) | 86,451 | 1,701,356 | |
GE HealthCare Technologies, Inc. | 206,461 | 15,740,587 | |
Glaukos Corp. (a) | 23,205 | 2,227,680 | |
Globus Medical, Inc. Class A (a) | 58,173 | 2,896,434 | |
Hologic, Inc. (a) | 121,061 | 9,172,792 | |
IDEXX Laboratories, Inc. (a) | 41,864 | 20,628,905 | |
Inari Medical, Inc. (a) | 25,866 | 965,836 | |
Inspire Medical Systems, Inc. (a) | 14,919 | 3,605,326 | |
Insulet Corp. (a) | 35,082 | 6,031,999 | |
Integer Holdings Corp. (a) | 16,828 | 1,878,510 | |
Integra LifeSciences Holdings Corp. (a) | 33,523 | 977,866 | |
Intuitive Surgical, Inc. (a) | 177,405 | 65,749,841 | |
iRadimed Corp. | 4,435 | 180,105 | |
iRhythm Technologies, Inc. (a) | 15,428 | 1,690,600 | |
LeMaitre Vascular, Inc. | 9,934 | 643,723 | |
LivaNova PLC (a) | 27,330 | 1,523,647 | |
Masimo Corp. (a) | 22,570 | 3,033,634 | |
Medtronic PLC | 669,997 | 53,760,559 | |
Nevro Corp. (a) | 17,566 | 185,848 | |
Novocure Ltd. (a) | 51,982 | 636,260 | |
Omnicell, Inc. (a) | 22,831 | 612,099 | |
Orthofix Medical, Inc. (a) | 16,670 | 216,710 | |
Paragon 28, Inc. (a) | 18,765 | 173,013 | |
Penumbra, Inc. (a) | 18,477 | 3,630,176 | |
PROCEPT BioRobotics Corp. (a) | 22,998 | 1,218,434 | |
Pulmonx Corp. (a) | 17,591 | 133,868 | |
QuidelOrtho Corp. (a) | 25,359 | 1,028,307 | |
ResMed, Inc. | 74,141 | 15,865,433 | |
Shockwave Medical, Inc. (a) | 18,617 | 6,147,147 | |
SI-BONE, Inc. (a) | 19,131 | 272,808 | |
Steris PLC | 49,807 | 10,188,520 | |
Stryker Corp. | 172,312 | 57,982,988 | |
Tandem Diabetes Care, Inc. (a) | 32,406 | 1,188,976 | |
Teleflex, Inc. | 23,747 | 4,957,186 | |
TransMedics Group, Inc. (a) | 16,537 | 1,556,628 | |
Treace Medical Concepts, Inc. (a) | 22,788 | 236,312 | |
Varex Imaging Corp. (a) | 20,268 | 329,355 | |
Zimmer Biomet Holdings, Inc. | 105,336 | 12,669,814 | |
558,254,907 |
Quarterly Report | 3 |
Common Stocks – continued | |||
Shares | Value | ||
HEALTH CARE EQUIPMENT & SUPPLIES – continued | |||
Health Care Supplies – 1.3% | |||
Align Technology, Inc. (a) | 36,679 | $ 10,357,416 | |
Atrion Corp. | 677 | 286,567 | |
Avanos Medical, Inc. (a) | 23,279 | 420,884 | |
Cooper Cos., Inc. | 99,857 | 8,893,264 | |
DENTSPLY SIRONA, Inc. | 106,930 | 3,208,969 | |
Embecta Corp. | 28,401 | 287,702 | |
Establishment Labs Holdings, Inc. (a) | 9,577 | 478,946 | |
Haemonetics Corp. (a) | 25,519 | 2,346,472 | |
ICU Medical, Inc. (a) | 10,292 | 1,007,793 | |
Lantheus Holdings, Inc. (a) | 34,379 | 2,287,579 | |
Merit Medical Systems, Inc. (a) | 28,976 | 2,147,122 | |
Neogen Corp. (a) | 103,710 | 1,278,744 | |
OraSure Technologies, Inc. (a) | 38,741 | 204,940 | |
OrthoPediatrics Corp. (a) | 8,563 | 253,722 | |
RxSight, Inc. (a) | 13,568 | 707,300 | |
Solventum Corp. (a) | 73,854 | 4,801,249 | |
STAAR Surgical Co. (a) | 19,411 | 892,130 | |
UFP Technologies, Inc. (a) | 3,695 | 760,948 | |
40,621,747 | |||
TOTAL HEALTH CARE EQUIPMENT & SUPPLIES | 598,876,654 | ||
HEALTH CARE PROVIDERS & SERVICES – 20.7% | |||
Health Care Distributors – 2.6% | |||
AdaptHealth Corp. (a) | 36,868 | 363,150 | |
Cardinal Health, Inc. | 124,222 | 12,799,835 | |
Cencora, Inc. | 85,981 | 20,553,758 | |
Henry Schein, Inc. (a) | 65,330 | 4,526,062 | |
McKesson Corp. | 67,063 | 36,026,914 | |
Owens & Minor, Inc. (a) | 34,712 | 858,775 | |
Patterson Cos., Inc. | 42,052 | 1,071,064 | |
PetIQ, Inc. (a) | 13,899 | 226,832 | |
76,426,390 | |||
Health Care Facilities – 1.9% | |||
Acadia Healthcare Co., Inc. (a) | 46,389 | 3,430,003 | |
Brookdale Senior Living, Inc. (a) | 89,556 | 608,085 | |
Community Health Systems, Inc. (a) | 69,037 | 227,822 | |
Encompass Health Corp. | 50,361 | 4,199,100 | |
Ensign Group, Inc. | 28,558 | 3,380,125 | |
HCA Healthcare, Inc. | 101,164 | 31,342,630 | |
National HealthCare Corp. | 7,069 | 642,360 | |
Select Medical Holdings Corp. | 54,435 | 1,544,321 | |
Surgery Partners, Inc. (a) | 34,996 | 873,150 | |
Tenet Healthcare Corp. (a) | 46,209 | 5,188,809 | |
U.S. Physical Therapy, Inc. | 7,577 | 769,141 | |
Universal Health Services, Inc. Class B | 30,776 | 5,245,154 | |
57,450,700 |
| |||
Shares | Value | ||
Health Care Services – 4.7% | |||
23andMe Holding Co. Class A (a) | 133,881 | $ 67,235 | |
Accolade, Inc. (a) | 35,726 | 272,589 | |
Addus HomeCare Corp. (a) | 8,291 | 797,180 | |
Agiliti, Inc. (a) | 19,724 | 200,199 | |
agilon health, Inc. (a) | 153,066 | 841,863 | |
Amedisys, Inc. (a) | 16,469 | 1,515,971 | |
AMN Healthcare Services, Inc. (a) | 19,027 | 1,141,239 | |
Astrana Health, Inc. (a) | 23,521 | 873,805 | |
Castle Biosciences, Inc. (a) | 12,452 | 262,613 | |
Chemed Corp. | 7,222 | 4,102,096 | |
Cigna Group | 147,439 | 52,641,621 | |
CorVel Corp. (a) | 4,734 | 1,130,716 | |
Cross Country Healthcare, Inc. (a) | 17,643 | 310,517 | |
CVS Health Corp. | 648,455 | 43,906,888 | |
DaVita, Inc. (a) | 27,692 | 3,849,465 | |
DocGo, Inc. (a) | 46,112 | 155,859 | |
Enhabit, Inc. (a) | 21,312 | 215,038 | |
Fulgent Genetics, Inc. (a) | 9,325 | 189,764 | |
Guardant Health, Inc. (a) | 58,146 | 1,046,628 | |
Hims & Hers Health, Inc. (a) | 70,944 | 888,928 | |
Laboratory Corp. of America Holdings | 42,809 | 8,620,448 | |
LifeStance Health Group, Inc. (a) | 47,740 | 295,033 | |
ModivCare, Inc. (a) | 5,495 | 128,968 | |
National Research Corp. | 7,644 | 261,807 | |
NeoGenomics, Inc. (a) | 64,401 | 896,462 | |
Opko Health, Inc. (a) | 208,893 | 254,849 | |
Option Care Health, Inc. (a) | 89,347 | 2,670,582 | |
Pediatrix Medical Group, Inc. (a) | 40,822 | 362,091 | |
Pennant Group, Inc. (a) | 14,852 | 310,555 | |
Premier, Inc. Class A | 59,901 | 1,250,733 | |
Privia Health Group, Inc. (a) | 47,048 | 865,683 | |
Quest Diagnostics, Inc. | 56,617 | 7,823,337 | |
R1 RCM, Inc. (a) | 84,047 | 1,032,938 | |
RadNet, Inc. (a) | 29,119 | 1,412,272 | |
140,595,972 | |||
Managed Health Care – 11.5% | |||
Alignment Healthcare, Inc. (a) | 50,649 | 260,842 | |
Centene Corp. (a) | 269,175 | 19,665,926 | |
Clover Health Investments Corp. (a) | 185,672 | 116,973 | |
Elevance Health, Inc. | 118,408 | 62,588,101 | |
HealthEquity, Inc. (a) | 43,235 | 3,411,674 | |
Humana, Inc. | 62,030 | 18,738,643 | |
Molina Healthcare, Inc. (a) | 29,374 | 10,048,845 | |
Progyny, Inc. (a) | 43,747 | 1,402,529 | |
UnitedHealth Group, Inc. | 466,076 | 225,440,961 | |
341,674,494 | |||
TOTAL HEALTH CARE PROVIDERS & SERVICES | 616,147,556 |
4 | Quarterly Report |
Schedule of Investments (Unaudited)–continued
Common Stocks – continued | |||
Shares | Value | ||
HEALTH CARE TECHNOLOGY – 0.8% | |||
Health Care Technology – 0.8% | |||
Certara, Inc. (a) | 56,012 | $ 958,365 | |
Definitive Healthcare Corp. (a) | 25,544 | 177,275 | |
Doximity, Inc. Class A (a) | 55,165 | 1,339,958 | |
Evolent Health, Inc. Class A (a) | 52,183 | 1,447,556 | |
GoodRx Holdings, Inc. Class A (a) | 40,110 | 284,781 | |
Health Catalyst, Inc. (a) | 27,463 | 170,820 | |
HealthStream, Inc. | 12,299 | 316,945 | |
Multiplan Corp. (a) | 131,093 | 85,184 | |
Phreesia, Inc. (a) | 26,622 | 552,140 | |
Schrodinger, Inc. (a) | 31,762 | 774,358 | |
Sharecare, Inc. (a) | 169,547 | 121,379 | |
Simulations Plus, Inc. | 7,774 | 352,551 | |
Teladoc Health, Inc. (a) | 83,321 | 1,062,343 | |
Veeva Systems, Inc. Class A (a) | 77,064 | 15,301,828 | |
TOTAL HEALTH CARE TECHNOLOGY | 22,945,483 | ||
LIFE SCIENCES TOOLS & SERVICES – 11.3% | |||
Life Sciences Tools & Services – 11.3% | |||
10X Genomics, Inc. Class A (a) | 44,630 | 1,306,766 | |
Adaptive Biotechnologies Corp. (a) | 49,560 | 129,847 | |
Agilent Technologies, Inc. | 147,640 | 20,232,586 | |
Avantor, Inc. (a) | 341,041 | 8,263,423 | |
Azenta, Inc. (a) | 25,296 | 1,327,028 | |
BioLife Solutions, Inc. (a) | 19,035 | 333,874 | |
Bio-Rad Laboratories, Inc. Class A (a) | 10,918 | 2,945,130 | |
Bio-Techne Corp. | 79,627 | 5,033,223 | |
Bruker Corp. | 45,390 | 3,540,874 | |
Charles River Laboratories International, Inc. (a) | 25,763 | 5,899,727 | |
CryoPort, Inc. (a) | 24,483 | 396,380 | |
Cytek Biosciences, Inc. (a) | 53,459 | 321,289 | |
Danaher Corp. | 353,713 | 87,232,700 | |
Fortrea Holdings, Inc. (a) | 44,025 | 1,610,875 | |
Illumina, Inc. (a) | 80,092 | 9,855,321 | |
IQVIA Holdings, Inc. (a) | 91,963 | 21,314,264 | |
Maravai LifeSciences Holdings, Inc. Class A (a) | 57,033 | 467,671 | |
MaxCyte, Inc. (a) | 43,363 | 157,408 | |
Medpace Holdings, Inc. (a) | 12,382 | 4,808,550 | |
Mesa Laboratories, Inc. | 2,604 | 276,232 | |
Mettler-Toledo International, Inc. (a) | 10,933 | 13,444,310 | |
OmniAb, Inc. (a) | 45,347 | 201,341 | |
OmniAb, Inc. (a)(b) | 3,335 | 13,907 | |
OmniAb, Inc. (a)(b) | 3,335 | 13,006 | |
Pacific Biosciences of California, Inc. (a) | 120,052 | 198,086 | |
Quanterix Corp. (a) | 18,076 | 291,385 | |
Repligen Corp. (a) | 26,810 | 4,402,202 | |
Revvity, Inc. | 62,057 | 6,358,981 |
| |||
Shares | Value | ||
Sotera Health Co. (a) | 49,747 | $ 557,166 | |
Standard BioTools, Inc. (a) | 104,493 | 259,143 | |
Thermo Fisher Scientific, Inc. | 194,695 | 110,726,940 | |
Waters Corp. (a) | 29,797 | 9,208,465 | |
West Pharmaceutical Services, Inc. | 37,299 | 13,333,646 | |
TOTAL LIFE SCIENCES TOOLS & SERVICES | 334,461,746 | ||
PHARMACEUTICALS – 28.9% | |||
Pharmaceuticals – 28.9% | |||
Amneal Pharmaceuticals, Inc. (a) | 61,834 | 374,096 | |
Amphastar Pharmaceuticals, Inc. (a) | 19,540 | 806,025 | |
Amylyx Pharmaceuticals, Inc. (a) | 22,121 | 40,039 | |
AN2 Therapeutics, Inc. (a) | 10,392 | 24,941 | |
ANI Pharmaceuticals, Inc. (a) | 8,247 | 544,302 | |
Arvinas, Inc. (a) | 29,165 | 926,572 | |
Axsome Therapeutics, Inc. (a) | 15,362 | 1,133,101 | |
Bristol-Myers Squibb Co. | 1,025,308 | 45,052,034 | |
Cassava Sciences, Inc. (a) | 19,618 | 434,539 | |
Catalent, Inc. (a) | 91,110 | 5,088,494 | |
Collegium Pharmaceutical, Inc. (a) | 16,303 | 602,070 | |
Corcept Therapeutics, Inc. (a) | 44,701 | 1,042,427 | |
Edgewise Therapeutics, Inc. (a) | 17,100 | 306,774 | |
Elanco Animal Health, Inc. (a) | 249,113 | 3,278,327 | |
Eli Lilly & Co. | 406,609 | 317,602,290 | |
Enliven Therapeutics, Inc. (a) | 7,290 | 126,773 | |
Evolus, Inc. (a) | 23,673 | 278,631 | |
EyePoint Pharmaceuticals, Inc. (a) | 22,157 | 389,963 | |
Harmony Biosciences Holdings, Inc. (a) | 16,539 | 511,221 | |
Harrow, Inc. (a) | 15,358 | 156,498 | |
Innoviva, Inc. (a) | 28,146 | 425,286 | |
Intra-Cellular Therapies, Inc. (a) | 43,567 | 3,128,546 | |
Jazz Pharmaceuticals PLC (a) | 30,027 | 3,325,490 | |
Johnson & Johnson | 1,213,031 | 175,392,152 | |
Ligand Pharmaceuticals, Inc. (a) | 8,253 | 576,802 | |
Liquidia Corp. (a) | 22,959 | 295,023 | |
Longboard Pharmaceuticals, Inc. (a) | 10,797 | 229,976 | |
Merck & Co., Inc. | 1,276,894 | 165,000,243 | |
Organon & Co. | 127,936 | 2,380,889 | |
Pacira BioSciences, Inc. (a) | 23,067 | 605,509 | |
Perrigo Co. PLC | 68,455 | 2,235,740 | |
Pfizer, Inc. | 2,845,208 | 72,894,229 | |
Phathom Pharmaceuticals, Inc. (a) | 13,540 | 122,266 | |
Phibro Animal Health Corp. Class A | 10,290 | 171,843 | |
Pliant Therapeutics, Inc. (a) | 22,469 | 265,584 | |
Prestige Consumer Healthcare, Inc. (a) | 25,097 | 1,800,961 | |
Revance Therapeutics, Inc. (a) | 51,212 | 184,875 | |
Royalty Pharma PLC Class A | 191,492 | 5,304,328 | |
Scilex Holding Co. (a) | 34,921 | 26,815 | |
SIGA Technologies, Inc. | 22,645 | 198,823 | |
Supernus Pharmaceuticals, Inc. (a) | 26,842 | 807,944 |
Quarterly Report | 5 |
Common Stocks – continued | |||
Shares | Value | ||
PHARMACEUTICALS – continued | |||
Pharmaceuticals – continued | |||
Tarsus Pharmaceuticals, Inc. (a) | 11,215 | $ 352,488 | |
Terns Pharmaceuticals, Inc. (a) | 15,322 | 77,376 | |
Theravance Biopharma, Inc. (a) | 17,629 | 148,789 | |
Tilray Brands, Inc. (a) | 400,237 | 988,585 | |
Viatris, Inc. | 605,203 | 7,002,199 | |
WaVe Life Sciences Ltd. (a) | 41,720 | 205,680 | |
Zoetis, Inc. | 231,339 | 36,838,422 | |
TOTAL PHARMACEUTICALS | 859,705,980 | ||
TOTAL COMMON STOCKS (Cost $2,387,171,720) | 2,968,173,944 | ||
Money Market Fund – 0.1% | |||
State Street Institutional Treasury Plus Money Market Fund 5.24% (c) (Cost $3,434,000) | 3,434,000 | 3,434,000 | |
TOTAL INVESTMENT IN SECURITIES – 99.9% (Cost $2,390,605,720) | 2,971,607,944 | ||
NET OTHER ASSETS (LIABILITIES) (d) – 0.1% | 3,065,070 | ||
NET ASSETS – 100.0% | $2,974,673,014 |
Legend | ||
(a) | Non-income producing. | |
(b) | Level 3 security. | |
(c) | The rate quoted is the annualized seven-day yield of the fund at period end. | |
(d) | Includes $217,500 of cash collateral to cover margin requirements for futures contracts. |
Futures Contracts | |||||
Number of contracts | Expiration Date | Notional Amount | Value | Unrealized Appreciation/ (Depreciation) | |
Purchased | |||||
Equity Index Contracts | |||||
CME E-mini Health Care Select Sector Index Contracts (United States) | 37 | June 2024 | 5,275,090 | (118,332) | (118,332) |
CME E-mini Russell 2000 Index Contracts (United States) | 5 | June 2024 | 496,400 | (20,321) | (20,321) |
Total Equity Index Contracts | $(138,653) |
The notional amount of futures purchased as a percentage of Net Assets is 0.2%
Investment Valuation
Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Securities transactions are accounted for as of trade date. The Board of Trustees (the Board) has delegated the day to day responsibility for the valuation of the Fund’s investments to the Fair Value Committee (the Committee) established by the Fund's investment adviser. In accordance with valuation policies and procedures approved by the Board, the Fund attempts to obtain prices from one or more third party pricing vendors or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with procedures adopted by the Board. Factors used in determining fair value
6 | Quarterly Report |
Schedule of Investments (Unaudited)–continued
vary by investment type and may include market or investment specific event. The frequency with which these procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee oversees the Fund’s valuation policies and procedures and reports to the Board on the Committee’s activities and fair value determinations. The Board monitors the appropriateness of the procedures used in valuing the Fund’s investments and ratifies the fair value determinations of the Committee.
The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:
Level 1 – unadjusted quoted prices in active markets for identical investments
Level 2 – other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
Level 3 – unobservable inputs (including the Fund's own assumptions based on the best information available)
Valuation techniques used to value investments by major category are as follows:
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.
Futures contracts are valued at the settlement price established each day by the board of trade or exchange on which they are traded and are categorized as Level 1 in the hierarchy. Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy. If an unaffiliated open-end mutual fund’s NAV is unavailable, shares of that fund may be valued by another method that the Board believes reflects fair value in accordance with the Board’s fair value pricing policies and is categorized as Level 2 in the hierarchy.
Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.
Derivative Instruments
Risk Exposures and the Use of Derivative Instruments: The Fund's investment objectives allow the Fund to enter into various types of derivative contracts. Derivatives are investments whose value is primarily derived from underlying assets, indices or reference rates and may be transacted on an exchange or over-the-counter (OTC). Derivatives may involve a future commitment to buy or sell a specified asset based on specified terms, to exchange future cash flows at periodic intervals based on a notional principal amount, or for one party to make one or more payments upon the occurrence of specified events in exchange for periodic payments from the other party.
The Fund used derivatives to increase returns, to gain exposure to certain types of assets and/or to manage exposure to certain risks as defined below. The success of any strategy involving derivatives depends on analysis of numerous economic factors, and if the strategies for investment do not work as intended, the Fund may not achieve its objectives.
The Fund's use of derivatives increased or decreased its exposure to the following risk(s):
Equity Risk - Equity risk relates to the fluctuations in the value of financial instruments as a result of changes in market prices (other than those arising from interest rate risk or foreign exchange risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment.
Investing in derivatives may involve greater risks than investing in the underlying assets directly and, to varying degrees, may involve risk of loss in excess of any initial investment and collateral received. In addition, there may be the risk that the change in value of the derivative contract does not correspond to the change in value of the underlying instrument.
Futures Contracts: A futures contract is an agreement between two parties to buy or sell a specified underlying instrument for a specified price at a specified future date.
The Fund used futures contracts to manage its exposure to the stock market.
Open futures contracts at period end are presented in the Schedule of Investments under the caption "Futures Contracts". The underlying face amount at value reflects each contract's exposure to the underlying instrument or index at period end. Any securities and/or cash deposited to meet initial margin requirements are identified in the Schedule of Investments.
For additional information on the Fund’s significant accounting policies, please refer to the Fund’s most recent semiannual or annual shareholder report.
Quarterly Report | 7 |
The fund’s schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund’s shareholders. For more information regarding the fund and its holdings, please see the fund’s most recent prospectus and annual report.
Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.
8 | Quarterly Report |